As­traZeneca nabs 6 more months for Sym­bi­cort patent in lat­est court rul­ing

A fed­er­al judge in West Vir­ginia ruled in fa­vor of As­traZeneca on Wednes­day, adding six months of patent pro­tec­tion for its asth­ma and COPD in­haler block­buster Sym­bi­cort.

The lat­est rul­ing con­cerns a rel­a­tive­ly new patent pro­tec­tion that As­traZeneca had ob­tained ear­li­er this year. The new judge­ment on that case rules that My­lan (now Vi­a­tris) and Kinde­va Drug De­liv­ery in­fringed on five claims of that ‘588 patent.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.